Lower Extremity Peripheral Arterial Disease and Exercise Ischemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2018-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lower extremity peripheral arterial disease (LEPAD) is a highly prevalent chronic disease. Cardiovascular mortality of LEPAD patients at five years ranges between 18 to 30%. LEPAD is primarily caused by atherosclerosis that induces an inadequate blood flow to meet the tissues demand due to the narrowing of the arteries. An aggravation of the arterial lesions in LEPAD patients induces a worsening of patients' symptoms and a severe limitation of their walking capacity, contributing to an impairment of their quality of life. Despite maintaining a sufficient walking activity is essential for these patients, LEPAD patients lower their physical activity, which worsen the disease and potentially contribute to increase the risk of cardiovascular events and deaths.

In a recent study in LEPAD patients, we showed, from a one hour GPS recording, a high variability of the patients' walking capacity (i.e., walking distances between two stops induced by lower limbs pain). Results suggested that in most patients previous stop duration before each walk was a predictor parameter of this walking variability. Whether there is an optimal or minimal recovery time influencing the walking capacity in LEPAD patients has never been studied.

This study is a prospective, cross-sectional study in exercise pathophysiology.

The main goal is to determine, following a walk that induces ischemia, the influence of the recovery duration on the subsequent walking performance in LEPAD patients.

Secondary goals are :

1. To determine the nature of the relationship between the recovery duration and subsequent walking performance.
2. To study the relationship between exercise ischemia, pain evolution and previous recovery duration.
3. To determine whether the experimental procedure influence the determination of an optimal of minimal recovery duration.
4. To study the influence of recovery duration on walking capacity from community-based measurement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Claudication, Systematic Evaluation of Limp on Treadmill

NCT02754804

Peripheral Artery Disease

COMPLETED

MetfOrmin BenefIts Lower Extremities With Intermittent Claudication

NCT05132439

Intermittent Claudication

RECRUITING PHASE3

Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease

NCT04800276

Peripheral Arterial Disease

UNKNOWN NA

Activity To Improve Outcomes in Peripheral Arterial Disease

NCT02189018

Peripheral Arterial Occlusive Disease

COMPLETED NA

The RESPECT-PAD Trial

NCT03298230

Peripheral Arterial Disease Cardiovascular Diseases

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is expected to determine for the first time an optimal recovery duration that would maximize the walking capacity of LEPAD patients.

In the medium term :

* To give indications to the LEPAD patients to manage their pain in the community without lower their physical activity.
* To limit the functional decline of LEPAD patients.
* To influence the quality of life and cardiovascular mortality. This would deserve furthers studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Diseases Intermittent Claudication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subsequent walking performance

Group Type EXPERIMENTAL

Subsequent walking performance

Intervention Type OTHER

Subsequent walking performance

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Subsequent walking performance

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old
* Insured under the French social security system (according to French law)
* Presence of lower-extremity peripheral artery disease, defined by:

* A resting ankle-brachial index (ABI) ≤ 0.90
* OR if resting ABI \> 0.90 and \< 1.00, a decrease in recovery ankle systolic pressure or in recovery ABI from treadmill exercise higher than 30% or 20%, respectively (AHA recommendations).
* OR if resting ABI \> 1.40, a toe pressure index ≤ 0.70
* Maximal walking distance on treadmill (3.2 km/h, 10% grade) \< 500m (a)
* Complain of exertional lower limbs pain that can begin or not at rest, causes the participant to stop walking and relieves or lessens within 10 minutes of rest (assessed using the San Diego questionnaire AND confirmed during treadmill testing) (b)

1. As assessed during the medical appointment.

i) Intermittent claudication. Patients that experience exertional calf pain that does not begin at rest and that forces them to stop walking and that relieves or lessens within 10 minutes of rest; ii) Atypical exertional leg pain/stop. This category can encompass diverse situations of exertional leg symptoms. In the present study, patients in this category were included if they experience exertional pain that does not begin at rest and that forces them to stop walking, but that do not involve only the calf(s) but also thigh(s) and/or buttock(s). Further, the exertional leg pain relieves or lessens within 10 minutes of rest; iii) Leg pain on exertion and rest. In this category, patients sometimes experience exertional leg pain at rest when they are standing still or sitting. On exertion, patients also experience a walking pain as described above. As reminded by Criqui et al., this category of patients with "pain at rest" should not be confused with patients that experience "rest pain", which usually refers to patients with such severe advanced PAD that ischemic pain is present even at rest. Patients with ischemic rest pain were not included in the study.

* Exercise limitation due to symptoms not related to an arterial insufficiency in the lower limbs (e.g., dyspnea, angina pectoris)
* Contraindication for walking (Abdominal aortic aneurysm \> 4 cm)
* Myocardial infarction and no stroke in the last 3 months
* Critical limb ischemia, amputation.
* Pregnant women
* Adult subject to legal protection (guardianship or tutelage measure) and persons deprived from their liberty (according to French law).
* Patient living more than 50 km from the university hospital
* Patient unable to understand the instructions of the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No